FDA Approved: EMGALITY — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for Emgality (galcanezumab) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Emgality (galcanezumab)

Snippet

SUPPL AP for EMGALITY (GALCANEZUMAB-GNLM)